Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetesByJamie Wood, MDJune 4th 2026
Kevin Kaiserman, MD, discusses the impact of the first inhaled insulin approval for pediatricsByKevin Kaiserman, MDMay 29th 2026
FDA approves inhaled insulin Afrezza for children and adolescents with diabetesByMorgan Ebert, Executive EditorMay 29th 2026
Early antibiotic exposure shows limited link to pediatric T1D riskByCeleste Krewson, Assistant EditorMay 22nd 2026
Mental health disorders affect more than 1 in 4 pediatric patients with diabetesByHannah Murphy, PhDMay 15th 2026